Drugs / Leptin A-200
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01710722 | Feb 2001 → Feb 2002 | obesity disorder | Pennington Biomedical Research Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leptin A-200 | “Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.” NCT01710722 ↗ |
| Known as | recombinant methionyl human Fc-leptin | “leptin A-200 (recombinant methionyl human Fc-leptin, 20 mg q.d.) (L)” PMID 23686786 ↗ Jun 2013 |
| Modality | Protein / enzyme biologic | “leptin A-200 (recombinant methionyl human Fc-leptin, 20 mg q.d.) (L)” PMID 23686786 ↗ Jun 2013 |
| Route | Subcutaneous | “Leptin A-200 20 mg subcutaneously once daily” NCT01710722 ↗ |